AASLD2019[473]473 安罗华仙丸结合肠溶治疗 提高患有以下疾病的

StephenW

473
ANLUOHUAXIANWAN COMBINED WITH ENTECAVIR THERAPY
ENHANCES FIBROSIS IMPROVEMENT RATE IN PATIENTS WITH
CHB: A MULTICENTER, RANDOMIZED, PROSPECTIVE STUDY
Liang Miao1,2, Wan-Na Yang1, Xiaoqin Dong1, Hong Zhao1 and
Guiqiang Wang3, (1)Infectious Diseases, Peking University
First Hospital, (2)Center of Diseases, The Third Hospital of
Qinhuangddao, (3)Department of Infectious Diseases, Peking
University First Hospital
Background: Limited reliable data are available regarding
changes in fibrosis in patients treated with anluohuaxianwan
(ALHXW) combined with entecavir (ETV). The aim of this study
was to evaluate changes in fibrosis between groups treated
with ALHXW combined with ETV and ETV alone. Methods:
219 consecutive chronic hepatitis B (CHB) paired liver
biopsies obtained before and after treatment from patients in
mainland China were analyzed, including 77 in the ETV group
and 142 in the ALHXW combined with ETV group. Histological
grading and staging were assessed using the Ishak scoring
system Results: In patients with Ishak score ≥3 at baseline,
the fibrosis improvement rate of combined therapy after 78
weeks (54.74%, 52/95) was significantly higher than that of
the monotherapy group (33 33%,16/48), P =0 016; In patients
with Ishak score <3 at baseline, the rate of patients with
increased fibrosis in the combination group (31.91%, 15/47 )
was less than that of the monotherapy group (48 28%,14/29)
Multivariate analyses addressed that combination therapy
(OR=2.655, P=0.038), high baseline fibrosis stage
(OR=1 797, P=0 019), low HBsAg (OR=1 951, P=0 029),
and young age (OR=0 954, P=0 014) were associated with
fibrosis regression after 78 weeks intervention. Conclusion:
Significantly higher fibrosis improvement rate was found in
ALHXW combined with ETV therapy for 78 weeks in patients
with baseline Isake score ≥ 3. Of these patients, high baseline
fibrosis stage (Ishak score ≥3), low HBsAg, and young age
potentially predicte regression.

StephenW

473
安罗华仙丸结合肠溶治疗
提高患有以下疾病的患者的纤维化改善率
CHB：多中心，随机，前瞻性研究
梁M1,2，杨万娜1，小琴东1，洪昭1和
王桂强3，（1）北京大学传染病
第一医院，（2）疾病预防控制中心，第三医院
秦皇岛，（3）北京大学传染病系
大学第一医院
背景：关于以下方面的可靠数据有限
安洛华仙丸治疗患者纤维化的变化
（ALHXW）联合恩替卡韦（ETV）。这项研究的目的
评估治疗组之间纤维化的变化
与ALHXW结合单独使用ETV和ETV。方法：
219个连续的慢性乙型肝炎（CHB）配对肝
治疗前后从患者体内获得的活检
分析了中国大陆，其中包括ETV集团的77家
ALHXW中的142个与ETV集团合并。组织学
使用Ishak评分评估分级和分期
系统结果：在基线时Ishak得分≥3的患者中，
78后联合治疗的纤维化改善率
周（54.74％，52/95）显着高于
单一疗法组（33 33％，16/48），P = 0 016;在患者中
基线时Ishak得分<3的患者
联合治疗组纤维化增加（31.91％，15/47）
低于单药治疗组（48 28％，14/29）
多变量分析解决了联合治疗
（OR = 2.655，P = 0.038），高基线纤维化阶段
（OR = 1 797，P = 0.019），低HBsAg（OR = 1 951，P = 0.029），
和年轻年龄（OR = 0 954，P = 0 014）与
干预78周后纤维化消退。结论：
发现有较高的纤维化改善率
ALHXW联合ETV治疗患者78周
基线Isake得分≥3的患者中，基线较高
纤维化阶段（Ishak评分≥3），低HBsAg和年轻
潜在地预测回归。